Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPC4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPC4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GPC4 Products |
| Gene Delivery | GPC4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View GPC4 Products |
| Benchmark Ab | Anti-GPC4 (Recombinant positive control) Sequence Verified. |
View GPC4 Products |
| Validator | GPC4 siRNA Set For knockdown verification. |
View GPC4 Products |
| Related Target A | GPC3 Critical for subfamily counter-screening and specificity validation. |
View GPC3 Products |
| Related Target B | WNT3A Synergistic pathway partner in Wnt signaling activation. |
View WNT3A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (vs GPC1, GPC3) | Homolog panel proteins strictly verified by mass spec and sequence analysis. |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity. |
| Lack of Controls | Recombinant Benchmark Antibodies included for assay standardization. |
| False Positives in Cell Assays | Valid siRNA included for specificity checks and background knockdown. |
Live GPC4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPC4 therapeutics is intensifying, with early-stage players exploring its potential beyond the well-established GPC3 landscape. As an emerging cell surface heparan sulfate proteoglycan, GPC4 is highly implicated in Wnt signaling and tumor progression. The next wave of R&D is targeting Antibody-Drug Conjugates (ADCs) and bispecifics to leverage its differential expression in specific solid tumors and metabolic disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Early Stage Biotech | Solid Tumors (e.g., HCC, GI) | Internalization Assay (Need high-purity ECD-Fc) |
| Bispecific | Preclinical Innovators | Immunotherapy | Heterodimer Validation (Need Cross-reactive Abs) |
| CAR-T | Academic/Translational | Refractory Cancers | Target Binding Validation (Need Native-like Lentivirus Cell Lines) |